ClinicalTrials.gg
CompletedNCT01902641Updated Jul 18, 2013

Muscle Relaxation for Short Procedures

An interventional study of Succinylcholine and Rocuronium/Sugammadex in Intubating Conditions, Fasciculations and Postoperative Myalgia, sponsored by Dr. Horst Schmidt Klinik GmbH. Completed at 1 site in Germany. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-07-18.

Sponsored by Dr. Horst Schmidt Klinik GmbH · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies in Patient Satisfaction with a site in Germany — 3 open to participants now, 3 under way, none of them phase 3. Patient Satisfaction · Germany.

Enrollment
6th of 10
105 · median 123
Started
2011
the only one that year
No phase
7 of 22
3 open now
Registered
3rd of 22
by date
Lead sponsor
2 of 22
Dr. Horst Schmidt Klinik GmbH

Among the 22 studies in Patient Satisfaction with a site in Germany, this one is the 6th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2011, is one of 7 with no phase, and was the 3rd registered.

Patient Satisfaction

880 studies on the registry are indexed under Patient Satisfaction; 204 are open to participants now.

Browse Patient Satisfaction studies →

Open to participants now

3 of the 22 studies in Patient Satisfaction with a site in Germany are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 100 Patient Satisfaction studies recruiting now, 62 (62%) set no upper age limit and 30 (30%) stop at 75 or younger; 14 take children under 18; 26 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Patient Satisfaction with a site in Germany, or all of them as a file.
02

Study summary

Succinylcholine is commonly used for neuromuscular relaxation for short procedures such as rigid bronchoscopy. A more modern alternative is the application of low-dose rocuronium, reversed by low-dose sugammadex. The investigators compare the intubating conditions, incidence of postoperative myalgia (POM), as well as patient satisfaction for these two muscle relaxants.

03

Conditions studied

  • Intubating Conditions
  • Fasciculations
  • Postoperative Myalgia
  • Patient Satisfaction
  • Sore Throat

Keywords

  • succinylcholine
  • rocuronium
  • sugammadex
  • Intubating Conditions
  • short Procedures
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age > 18 yr
  • scheduled for elective rigid bronchoscopy

Exclusion criteria

Exclusion Criteria:

  • known neuromuscular disease
  • significant hepatic or renal dysfunction
  • family history of malignant hyperthermia
  • known allergy to one of the drugs used in this protocol
  • pregnancy or breastfeeding
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Single (Participant)
Enrollment
105 participants (actual)

Study arms

  • Active comparator
    Succinylcholine

    Patient received succinylcholine as a muscle relaxant(0.5 mg /kg)for induction of anaesthesia for rigid bronchoscopy.

    Drug: Succinylcholine

  • Active comparator
    Rocuronium/Sugammadex

    Patient received rocuronium (0.25 mg/ kg) as muscle relaxant for induction of anaesthesia for rigid bronchoscopy, at the end of procedure rocuronium was reversed with sugammadex (0.5mg/kg.)

    Drug: Rocuronium/Sugammadex

  • Active comparator
    Rocuronium

    Patients received rocuronium (0.25 mg /kg)as muscle relaxant for induction of anaesthesia for rigid bronchoscopy.

    Drug: Rocuronium

Interventions

  • Anaesthesia was induced and maintained with propofol (1-2 mg/kg) and remifentanil (0.5 µg/kg). The study arm was immobilized and a dual electrode for peripheral nerve stimulation was placed over the ulnar nerve near the wrist. Neuromuscular monitoring was performed with accelerometry.The patients received succinycholine according to the study group.

  • DrugRocuronium/Sugammadex

    Drug pages: Rocuronium · Sugammadex

    Anaesthesia was induced and maintained with propofol (1-2 mg/kg) and remifentanil (0.5 µg/kg). The study arm was immobilized and a dual electrode for peripheral nerve stimulation was placed over the ulnar nerve near the wrist. Neuromuscular monitoring was performed with accelerometry.The patients received rocuronium/sugammadex according to the study group.

  • Anaesthesia was induced and maintained with propofol (1-2 mg/kg) and remifentanil (0.5 µg/kg). The study arm was immobilized and a dual electrode for peripheral nerve stimulation was placed over the ulnar nerve near the wrist. Neuromuscular monitoring was performed with accelerometry.The patients received rocuronium according to the study group.

06

What researchers measure

Primary outcomes

  1. Intubating condition

    scoring system proposed for Good Clinical Research Practice using the following variables: conditions of inserting rigid bronchoscope, vocal cord position, and coughing

    Time frame: After induction of general anaesthesia (after 3-5 minutes)

Secondary outcomes

  1. Fasciculations

    Fasciculations were graded by the investigator on the following four-point scale 0 = no fasciculations 1. = mild, fine fasciculations of the eyes, neck, face or fingers, without limb movement 2. = moderate fasciculations occurring at more than two sites, or obvious limb movement 3. = vigorous or severe, sustained and widespread fasciculations in the trunk and limbs

    Time frame: After application of the neuromuscular blocking agent (after 3-5 min)

  2. Postoperative Myalgia (POM)

    The severity of POM was measured using a four-point scale 0 = no myalgia 1. = minor pain limited to one area of the body 2. = muscle pain or stiffness noticed spontaneously by the patient, which may have required analgesic therapy 3. = generalized, severe, or incapacitating discomfort

    Time frame: 72 Hours after Intervention

Other outcomes

  1. Sore throat

    Measurement on an numeric ten point scale, the patients receive a questionaire

    Time frame: 72 hours after intervention

  2. Patient Satisfaction

    Measurement on a numeric ten point scale the patients receive a questionaire

    Time frame: 72 Hours after intervention

07

Study locations

1 site
  • Dr. Horst Schmidt Kliniken
    Wiesbaden, 65199, Germany
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2011, a primary completion of Mar 2012 and a completion of Mar 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2013
First posted
Jul 18, 2013
Start
Oct 2011
Primary completionActual
Mar 2012
CompletionActual
Mar 2012
Last update
Jul 18, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 18, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01902641
Lead sponsor
Dr. Horst Schmidt Klinik GmbH
Responsible party
Sponsor
First posted
Jul 18, 2013
Start date
Oct 2011
Primary completion
Mar 2012
Completion
Mar 2012
Last update
Jul 18, 2013

Study contacts

Grietje Beck, Prof
study chair · Dr. Horst Schmidt Kliniken Wiesbaden Germany

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Succinylcholine · Rocuronium · Sugammadex

Start the discussion